The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...

The stock's fall snapped a three-day winning streak.

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

Merck & Co., Inc. ( NYSE: MRK) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M. Davis - ...

Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...